Storys zum Thema Pharma

08.04.2008 – 09:00
Roche Professional Diagnostics
Roche Diagnostics expands availability of HCV immunoassay
Rotkreuz, Switzerland (ots) - Roche Diagnostics announced today that the Elecsys Anti-HCV (Hepatitis C Virus) assay has received regulatory approval in Europe for the E 170 analyzer for MODULAR ANALYTICS and the e 601 module for the cobas 6000 platform. The Elecsys Anti-HCV assay is already available on the Elecsys 2010 and the cobas e 411 instruments. Hepatitis C virus (HCV) infection represents a major cause ...
mehr
27.03.2008 – 11:00
Pieris AG
Pieris raises EUR 25 M (US$ 38 M) in Series B financing round / New investment round led by OrbiMed Advisors, world?s largest healthcare investment firm
Freising-Weihenstephan, Germany (ots) - Pieris AG, a biopharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, announced today the closing of a Series B financing round. Led by new investor OrbiMed Advisors LLC, a major global fund dedicated to healthcare, ...
mehr
03.03.2008 – 18:00
Helsinn Healthcare SA
FDA approves ALOXI® (Palonosetron HCl) injection for prevention of postoperative nausea and vomiting
Lugano (ots) - Helsinn Healthcare SA, a Swiss pharmaceutical group, together with its partner EISAI Corporation of North America and EISAI's U.S. subsidiary, MGI Pharma, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Aloxi® (palonosetron hydrochloride) injection for the prevention of postoperative nausea and vomiting (PONV) for ...
mehr
13.02.2008 – 12:00
Helsinn Healthcare SA
Helsinn Healthcare SA and Riemser Arzneimittel AG sign a license agreement for Aloxi® (palonosetron) and Gelclair® in Germany
Lugano (ots) - Helsinn Healthcare SA, a Swiss pharmaceutical group, today announced that it has signed a Distribution and License Agreement for Aloxi® (Palonosetron hydrochloride) and Gelclair® in Germany with Riemser Arzneimittel AG, a medium-sized pharmaceutical group engaging in research, headquartered in ...
mehr
11.02.2008 – 11:08
Helsinn Healthcare SA
Helsinn Healthcare SA announces the launch of Aloxi® (Palonosetron) in the UK
Lugano, Switzerland (ots) - Helsinn Healthcare SA, a Swiss pharmaceutical group, is pleased to announce, ahead of schedule, today's launch in the UK of Aloxi® (Palonosetron hydrochloride), a new generation treatment for chemotherapy induced nausea and vomiting, by its local partner Maelor plc, the specialist hospital medicines group. Aloxi® is a patented ...
mehr
03.01.2008 – 18:00
Helsinn Healthcare SA
Helsinn and MGI Pharma announce sNDA for ALOXI Capsules accepted for review by U.S. FDA
LUGANO, Switzerland and MINNEAPOLIS, MN (ots) - Helsinn Healthcare S.A., Switzerland, a privately owned pharmaceutical group and its partner, MGI Pharma (Nasdaq: MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that a supplemental New Drug Application (sNDA) for Aloxi® (palonosetron hydrochloride) Capsules for oral ...
mehr

21.12.2007 – 16:50
AmVac AG
Dr. Wolfgang Schmidt appointed AmVac AG COO
Zug (ots) - AmVac AG has a new executive officer on board - Dr. Wolfgang Schmidt agreed to join the company in early December to lead its operational business. Dr. Wolfgang Schmidt is a graduated chemist who began his career with Hoechst AG in Frankfurt/Main, Germany. After a variety of stints in pharmaceutical research, he directed the site-management Frankfurt department in the lead generation research segment. ...
mehr
29.11.2007 – 09:30
biolytix AG
Biolytix to Offer Industrial Gene Expression Analysis and Genotyping Services Using Affymetrix' GeneChip® Technology
Witterswil (ots) - Biolytix AG (www.biolytix.ch) signed a service provider agreement with Affymetrix UK Ltd (www.affymetrix.com) and offers genomic analysis services for the academic and industrial R&D community under conditions compliant with a stringent quality management system. Biolytix, one of the ...
mehr
30.10.2007 – 11:28
Helsinn Healthcare SA
Helsinn Healthcare and MGI PHARMA announce submission of supplemental new drug application for Aloxi® oral capsules
Lugano (ots) - Oral Formulations of 5-HT3 receptor Antagonists Represent Approximately 10% of the Day-of-Chemotherapy Market - Helsinn Healthcare SA, a privately owned Swiss pharmaceutical group, and its partner MGI PHARMA, INC., (Nasdaq: MOGN), a biopharmaceutical company focused in oncology and acute care, ...
mehr
23.10.2007 – 13:19
TRB Chemedica International S.A.
Paris court will rule on the distribution rights for Gilead products in Switzerland
Geneva (ots) - TRB Chemedica International S.A. has issued legal proceedings against Gilead Science Limited in a dispute over the distribution rights of their products Viread, Hepsera, Truvada and Emtriva for Switzerland. TRB Chemedica International S.A., a small, family-owned Swiss pharmaceutical company based in Geneva, was granted exclusive rights by ...
mehr
11.10.2007 – 14:05
Grünenthal GmbH
Micropill Belara® improves impure skin
Paris (ots) - At this year's 7th congress of the European Society of Gynaecology (Paris, 10-14 October 2007), the German pharmaceutical company Grunenthal GmbH presents the latest study results for its oral contraceptive Belara®. As the first of its kind the dermatological CEFIS-Study* of the University of Hamburg shows an impressive cosmetic improvement of impured skin due to the anti-androgenic properties of ...
mehr
08.10.2007 – 09:00
Prionics AG
Prionics enhances its European presence
Former Cedi-Diagnostics new affiliate for the Benelux and Nordic markets Zurich (ots) - Prionics, a world leader in farm animal diagnostics, enhances its own presence in Europe targeting the Benelux and Nordic markets with the launch of Prionics Lelystad (Netherlands). The latest affiliate emerges from the former Cedi-Diagnostics B.V. acquired in 2006, a spin-off from today's world-famous Animal Sciences Group of ...
mehr

01.10.2007 – 14:05
Grünenthal GmbH
Centrally acting analgesic tapentadol - latest phase II data for the treatment of acute postoperative pain presented
Aachen (ots) - At this year's 4th World Congress of the World Institute of Pain (WIP), the German pharmaceutical company Grunenthal GmbH presented the latest clinical data on its centrally active analgesic tapentadol in acute pain. Tapentadol combines two analgesic principles in one molecule, μ-receptor ...
mehr
21.09.2007 – 18:20
Helsinn Healthcare SA
The CHMP/EMEA has confirmed that the benefit/risk profile of Nimesulide is positive
London (ots) - Helsinn's Top Management today announced the positive outcome of the EMEA procedure, according to Article 107, initiated due to concerns over serious liver problems. The Committee for Medicinal Products for Human Use (CHMP) today confirmed Nimesulide's positive benefit/risk profile. The benefits of these medicines outweigh their risks, but there ...
mehr
07.09.2007 – 14:42
AmVac AG
Ariane Meynert Joins Swiss AmVac AG
Zug (ots) - As of September 1, 2007 Ariane Meynert is joining Swiss biotech company AmVac AG, Zug, as Managing Director in charge of investor and public relations. Management graduate Meynert comes from TOMORROW FOCUS AG in Munich, a Hubert Burda Medien AG Group company where she was in charge of developing investor and public relations for several years. She previously supervised, in the same function, the ...
mehr
05.09.2007 – 14:42
Pieris AG
Pieris validates the use of Anticalins® as ophthalmologic biotherapeutics
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced successful completion of a series of preclinical studies validating the use of Anticalins® in ophthalmologic disease. The studies reported by Pieris relate to PRS-055, an ...
mehr
05.09.2007 – 10:00
Pieris AG
Pieris validates the use of Anticalins® as ophthalmologic biotherapeutics
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced successful completion of a series of preclinical studies validating the use of Anticalins® in ophthalmologic disease. The studies reported by Pieris relate to PRS-055, an Anticalin® ...
mehr
04.09.2007 – 16:30
Boehringer Ingelheim
Prehospital Thrombolysis for AMI to be Studied in New Clinical Trial / Study will investigate concept that prehospital lysis can be at least as good as primary PCI
Ingelheim, Germany (ots) - For scientific media outside the USA, Canada and Japan Boehringer Ingelheim announced today that it is undertaking a new initiative in the treatment of heart attack (ST-segment elevation myocardial infarction or STEMI). The company will sponsor a new clinical trial known as ...
mehr

20.07.2007 – 09:30
Viroblock SA
Viroblock SA receives First Round of Equity Funding
Plan-les-Ouates (ots) - Viroblock SA, a start-up dedicated to developing and commercializing a new generation of antiviral products, today announced that it has completed its first round of equity funding led by private investor Peter Pfister, Fongit Seed Invest SA, and Initiative Capital Romandie SA. Viroblock also announced that the newly appointed Board of Directors will consist of Peter Pfister (Chairman), ...
mehr
17.07.2007 – 11:45
Grünenthal GmbH
Grunenthal signs trimegestone licensing agreement for oral contraception
Aachen (ots) - The German pharmaceutical company Grunenthal announces its worldwide exclusive rights on trimegestone for the use in oral contraception by Aventis Pharma, SA, France, a subsidiary of sanofi-aventis. Thereby the firm extends its gynaecological pipeline. Trimegestone will be developed as a new oral contraceptive component derived from natural ...
mehr
12.07.2007 – 10:10
Helsinn Healthcare SA
Helsinn Healthcare SA Announces Aloxi sNDA for PONV accepted for review by U.S. FDA
PDUFA date of 4th March 4, 2008 established Lugano (ots) - Helsinn's Top Management today announced that the supplemental New Drug Application (sNDA) for Aloxi® (palonosetron hydrochloride) Injection for the prevention of post-operative nausea and vomiting was accepted for filing by the United States Food and Drug Administration (FDA). Aloxi is approved by the FDA ...
mehr
10.07.2007 – 10:00
Pieris AG
Pieris progresses proprietary asthma program: validation of pulmonary delivery of Anticalin®-based protein product candidate
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced significant progress in validating novel, effective products for the potential treatment of asthma. In studies of its proprietary ...
mehr
21.06.2007 – 13:37
Pieris AG
Pieris progresses development of its proprietary biotherapeutics platform: successful demonstration of dual targeting with Duocalin® technology
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, announced today that its proprietary Duocalin® technology has successfully demonstrated dual targeting potential. Commenting on this development, Dr ...
mehr
21.06.2007 – 12:14
Grünenthal GmbH
Phase II data show efficacy and tolerability of tapentadol in chronic pain treatment
Aachen (ots) - The German pharmaceutical company Grunenthal GmbH presented the first clinical evidence for the efficacy and tolerability of tapentadol ER (extended release) for patients suffering from chronic pain at the Annual Congress of the European League Against Rheumatism (EULAR), 13-16 June 2007, Barcelona, Spain. Tapentadol, a centrally acting analgesic, ...
mehr

13.06.2007 – 10:00
Bristol-Myers Squibb SA
ORENCIA® (Abatacept) Demonstrates Continued Improvement in Clinical Response Through 12 Months
Barcelona (ots) - New Results Represent Additional Data From a Study Showing Superior Efficacy of ORENCIA or Infliximab Compared to Placebo at Six Months Bristol-Myers Squibb Company (NYSE: BMY) today announced additional study results providing evidence of the efficacy and durability of response of ORENCIA(R) (abatacept) through 12 months in adults with ...
mehr
13.06.2007 – 09:45
Bristol-Myers Squibb SA
Study Results Supportive of Switching Directly to ORENCIA® From
Anti-Tumor Necrosis Factor (TNF) Therapy in Inadequately Responding Rheumatoid Arthritis Patients Barcelona (ots) - According to a new study, it is possible to safely switch directly to ORENCIA® from anti-TNF therapy in rheumatoid arthritis patients who have had an inadequate response to anti-TNF therapy. The results were announced today by Bristol-Myers ...
mehr
17.05.2007 – 11:56
Helsinn Healthcare SA
Helsinn Healthcare SA - Nimesulide is a safe drug
Lugano (ots) - With reference to the Irish Medicine Board (IMB) decision, mainly based on 6 cases of hepatic damage, to suspend the marketing and sale of nimesulide and following the request to the European Committee for Medicinal Products for Human Use (CHMP) to revise the benefit/risk profile of the drug, Helsinn Healthcare deems opportune to specify that nimesulide is a drug with a positive safety profile as ...
mehr
07.05.2007 – 14:00
Helsinn Healthcare SA
HELSINN announces submission of supplemental new drug application for Aloxi® injection in post-operativa nausea and vomiting in USA
Lugano (ots) - HELSINN HEALTHCARE SA, a privately owned Swiss pharmaceutical group, today announced that a supplemental New Drug Application (sNDA) for Aloxi® (palonosetron hydrochloride) Injection for the prevention of post-operative nausea and vomiting (PONV) has been submitted to the U.S. Food and Drug ...
mehr
24.04.2007 – 07:30
Spinelab AG
SpineLab raises CHF 4 million in first financing round
Winterthur (ots) - SpineLab AG, a privately held company, specialized in developing a dynamic stabilization system for the spine, announced today that it has raised CHF 4 million in a first financing round. Lead investors are BioMedInvest and VI Partners. Other participants are the management and Acceleration International. Gérard Moufflet, CEO and Founder of Acceleration International has been appointed Chairman of ...
mehr
19.04.2007 – 12:35
ProBioGen AG
ProBioGen, Germany and Minapharm, Egypt enter into development and co-promotion agreements
Berlin (ots) - ProBioGen and Minapharm jointly announced today that they have entered into two separate agreements to develop two therapeutic proteins, one exclusively for Minapharm and another second generation biopharmaceutical product for co-promotion. In the first agreement, ProBioGen will apply its proven cell generation process for biopharmaceutical cell ...
mehr

Vorherige3456789101112Nächste